Hormone receptors AR, ER, PR and growth factor receptor Her-2 expression in oral squamous cell carcinoma: Correlation with overall survival, disease-free survival and 10-year survival in a high-risk population
Data files
Apr 17, 2022 version files 18.90 KB
-
10-year_Survival.sav
-
Overall_and_Disease-Free_Survival.sav
-
README.txt
Abstract
Oral squamous cell carcinoma (OSCC) comprises most of head and neck neoplasms and is one of the highest-ranking and lethal cancers in Pakistan due to prevailing mouth habits. Growth and hormonal receptors act as prognostic markers and targets for therapy in some cancers, but their application in OSCC is largely unexplored. This study aimed to evaluate the expression of growth and hormonal receptors in OSCC patients and correlate it with 10-year, overall and disease-free survival. To achieve this objective, immunohistochemistry for Her-2, AR, ER and PR was performed on 100 formalin-fixed paraffin-embedded primary OSCC specimens. Receptor expression was correlated with mouth habits and clinicopathological features and patient survival was analyzed using Kaplan-Meier method and Cox regression univariate analysis. We observed that in 100 patients, there were 57 males and 43 females. Immunopositive Her-2 expression was observed in 21% of patients, AR in 13%, ER in 3% and 0% for PR. Patients with betel quid/areca nut mouth habits had significantly absent Her-2 expression (P=0.035). Also, Her-2 negative patients were also negative for AR expression (P=0.002). Her-2 positive patients had poor 10-year survival (P=0.041). A trend of low survival and high recurrence rate was observed in AR positive patients, but this was not significant (P=0.072). No statistically relevant correlations were seen in the case of ER and PR. In conclusion, Her-2 may be a valuable marker for predicting long-term prognosis of OSCC patients.
Methods
Data of 100 OSCC patients was collected retrospectively from patient medical records and subsequent follow-up visits at clinics. Patient demographics, risk factor usage history, clinical characteristics and survival were correlated with experimental data (biomarker expression). Overall survival (OS) (minimum follow up 60 months) and 10-year survival (minimum follow up 120 months) was taken as number of months from diagnosis until last follow-up (if alive) or date of death (if dead). Disease-free survival (DFS) was calculated as the number of months starting from surgery until date of recurrence or if no recurrence then until last follow-up (if alive) or date of death. SPSS version 19 (IBM, USA) was used for statistical analysis. Statistical tests included chi-square, Fisher's Exact test, logistic regression, Kaplan-Meier analysis and cox regression univariate analysis.
Usage notes
README file provided with this dataset details the descriptions for the dataset files and all the variables included in the files.